Aripiprazole

Aripiprazole
Clinical data
Pronunciation/ˌɛrɪˈpɪprəzoʊl/
AIR-ih-PIP-rə-zohl
Abilify /əˈbɪlɪfaɪ/
ə-BIL-if-eye
Trade namesAbilify, others
Other namesOPC-14597; OPC14597; OPC-31; OPC31; RDC-3317
AHFS/Drugs.comMonograph
MedlinePlusa603012
License data
Pregnancy
category
Routes of
administration		By mouth, intramuscular
Drug classAtypical antipsychotic
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability87%[7][12][13]
Protein binding>99%[7][12][13]
MetabolismLiver (mostly via CYP3A4 and 2D6[7][12][13])
MetabolitesDehydroaripiprazole
Elimination half-life75 hours (active metabolite is 94 hours)[7][12][13]
ExcretionKidney (27%; <1% unchanged)
feces (60%; 18% unchanged)[7][12][13]
Identifiers
IUPAC name
  • 7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.112.532
Chemical and physical data
FormulaC23H27Cl2N3O2
Molar mass448.39 g·mol−1
3D model (JSmol)
SMILES
  • Clc4cccc(N3CCN(CCCCOc2ccc1c(NC(=O)CC1)c2)CC3)c4Cl
InChI
  • InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29) Y
  • Key:CEUORZQYGODEFX-UHFFFAOYSA-N Y
  (verify)

Aripiprazole, sold under the brand name Abilify, among others, is an atypical antipsychotic[14] primarily used in the treatment of schizophrenia, bipolar disorder, and irritability associated with autism spectrum disorder;[14] other uses include as an add-on treatment for major depressive disorder and tic disorders.[14] Aripiprazole is taken by mouth or via injection into a muscle.[14]

Common side effects include restlessness, insomnia, transient weight gain, nausea, vomiting, constipation, dizziness, and mild sedation.[14] Serious side effects may include neuroleptic malignant syndrome, tardive dyskinesia, and anaphylaxis.[14] It is not recommended for older people with dementia-related psychosis due to an increased risk of death.[14] In pregnancy, there is evidence of possible harm to the fetus.[14][15] It is not recommended in women who are breastfeeding.[14] It has not been very well studied in people younger than 18 years old.[14]

Aripiprazole was approved for medical use in the United States in 2002.[14] It is available as a generic medication.[16] In 2022, it was the 106th most commonly prescribed medication in the United States, with more than 6 million prescriptions.[17][18] It is on the World Health Organization's List of Essential Medicines.[19]

  1. ^ "Aripiprazole Use During Pregnancy". Drugs.com. 22 August 2019. Archived from the original on 12 November 2020. Retrieved 7 February 2020.
  2. ^ https://www.tga.gov.au/resources/prescription-medicines-registrations/aripena-sun-pharma-anz-pty-ltd
  3. ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  4. ^ "Abilify Product information". Health Canada. 19 March 2018. Retrieved 16 February 2025.
  5. ^ "Abilify Asimtufii Product information". Health Canada. 17 January 2025. Retrieved 16 February 2025.
  6. ^ "Abilify Maintena Product information". Health Canada. 27 March 2014. Retrieved 16 February 2025.
  7. ^ a b c d e f Cite error: The named reference Abilify FDA label was invoked but never defined (see the help page).
  8. ^ Cite error: The named reference Abilify Asimtufii FDA label was invoked but never defined (see the help page).
  9. ^ "Abilify Maintena- aripiprazole kit". DailyMed. 30 January 2025. Retrieved 16 February 2025.
  10. ^ "Abilify Mycite- aripiprazole tablet with sensor". DailyMed. 31 January 2025. Retrieved 16 February 2025.
  11. ^ "Abilify EPAR". European Medicines Agency. 4 June 2004. Archived from the original on 15 April 2024. Retrieved 4 July 2024.
  12. ^ a b c d e "Abilify Tablets, Orodispersible Tablets, Oral Solution – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Otsuka Pharmaceuticals (UK) Ltd. 20 September 2013. Archived from the original on 4 March 2016. Retrieved 22 October 2013.
  13. ^ a b c d e "ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS" (PDF). European Medicines Agency. Otsuka Pharmaceutical Europe Ltd. Archived from the original (PDF) on 23 October 2013. Retrieved 22 October 2013.
  14. ^ a b c d e f g h i j k "Aripiprazole (Monograph)". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 26 November 2020. Retrieved 26 February 2019.
  15. ^ "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
  16. ^ British national formulary: BNF 76 (76th ed.). Pharmaceutical Press. 2018. p. 392. ISBN 978-0-85711-338-2.
  17. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  18. ^ "Aripiprazole Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  19. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.